Mijten Bencard (Dermatophagoides Pteronyssinus)

Dermatophagoides pteronyssinus, the active ingredient in Mijten Bencard, is an allergen extract presented as a cutaneous formulation for subcutaneous use. It is employed to treat allergic rhinitis and allergic asthma caused by Dermatophagoides pteronyssinus in patients with IgE‑mediated hypersensitivity. The therapy aims to modify the immune response and provide long‑term symptom relief.

GNH USA supplies Mijten Bencard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU regulatory standards and is distributed under strict quality controls.

Mijten Bencard is used in allergen immunotherapy to address diseases driven by house‑dust‑mite sensitisation.

Allergic rhinitis: reduces nasal congestion, sneezing and itching, improving quality of life. Allergic asthma: decreases bronchial hyper‑responsiveness and reduces reliance on rescue inhalers. Allergen immunotherapy: induces long‑term tolerance to Dermatophagoides pteronyssinus, decreasing overall allergic burden. Seasonal exacerbations: lessens frequency and severity of seasonal symptom flare‑ups in sensitised individuals.

Adverse reactions to Mijten Bencard are generally related to its immunogenic nature and route of administration.

Common Side Effects: - Local injection site erythema - Swelling at the injection site - Itching or pruritus at the site - Transient mild fever

Serious or Rare Side Effects: - Anaphylaxis: rapid onset systemic allergic reaction - Severe bronchospasm requiring emergency intervention - Angioedema affecting airway or facial tissues

Before prescribing Mijten Bencard, clinicians should evaluate several safety considerations.

Pregnancy: use only if clearly needed, as data are limited. Breastfeeding: weigh potential risks and benefits before administration. Severe uncontrolled asthma: contraindicated due to heightened anaphylaxis risk. Concomitant beta‑blocker therapy: may mask early signs of systemic reaction. Age restriction: not recommended for children under five years of age. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mijten Bencard may interact with other medicines that influence immune or allergic responses.

Major Interactions (Avoid): - Beta‑blockers: can exacerbate severity of anaphylactic reactions. - ACE inhibitors: may increase risk of angioedema during therapy. - Immunosuppressants: may diminish the intended immunomodulatory effect.

Moderate Interactions (Monitor Closely): - Antihistamines: may mask early systemic symptoms, requiring close observation. - Corticosteroids: may alter the immune response and affect tolerance development.